Johnson & Johnson Effective Income Tax Rate Reconciliation, Deduction, Other, Percent
Johnson & Johnson (JNJ) reported Effective Income Tax Rate Reconciliation, Deduction, Other, Percent of 0.80% for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-16.
Discontinued › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationDeductionsOther · last filed 2024-02-16
- Johnson & Johnson effective income tax rate reconciliation, deduction, other, percent for fiscal 2023 was 0.80%, a 42.86% decline from fiscal 2023.
- Johnson & Johnson effective income tax rate reconciliation, deduction, other, percent for fiscal 2023 was 1.40%, a 16.67% increase from fiscal 2022.
- Johnson & Johnson effective income tax rate reconciliation, deduction, other, percent for fiscal 2022 was 1.20%, a 20.00% decline from fiscal 2021.
- Johnson & Johnson effective income tax rate reconciliation, deduction, other, percent for fiscal 2021 was 1.50%, a 200.00% increase from fiscal 2019.
| Period end | Effective Income Tax Rate Reconciliation, Deduction, Other, Percent 12 month | Effective Income Tax Rate Reconciliation, Deduction, Other, Percent 12 month as first filed |
|---|---|---|
| 2023-12-31 | 0.80% 10-K · filed 2024-02-16 | |
| 2023-01-01 | 1.40% 10-K · filed 2024-02-16 | 1.30% 10-K · filed 2023-02-16 |
| 2022-01-02 | 1.20% 10-K · filed 2024-02-16 | 1.00% 10-K · filed 2022-02-17 |
| 2021-01-03 | 1.50% 10-K · filed 2023-02-16 | |
| 2019-12-29 | 0.50% 10-K · filed 2022-02-17 | |
| 2018-12-30 | 1.50% 10-K · filed 2021-02-22 | |
| 2017-12-31 | 2.10% 10-K · filed 2020-02-18 | |
| 2017-01-01 | 1.80% 10-K · filed 2019-02-20 | |
| 2016-01-03 | 0.00% 10-K · filed 2018-02-21 | |
| 2014-12-28 | 0.00% 10-K · filed 2017-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ELI LILLY & Co (LLY) | United States | $1,113.804B | 42.28 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |